# NHLRC1

## Overview
The NHLRC1 gene encodes the protein known as NHL repeat containing E3 ubiquitin protein ligase 1, commonly referred to as malin. Malin is an E3 ubiquitin ligase, a type of enzyme that plays a crucial role in the ubiquitination pathway, which tags proteins for degradation by the proteasome. Structurally, malin is characterized by a RING-type zinc finger domain, which is essential for its ligase activity, and multiple NHL-repeat domains that facilitate protein-protein interactions (Ianzano2005Lafora). Functionally, malin is involved in regulating glycogen metabolism through its interaction with laforin, a protein phosphatase, forming a complex that targets proteins involved in glycogen biosynthesis for degradation (Worby2008Malin; Couarch2011Lafora). Mutations in the NHLRC1 gene are linked to Lafora disease, a severe form of progressive myoclonus epilepsy, underscoring the gene's importance in maintaining normal cellular and neurological functions (Pondrelli2023Prognostic; Singh2005Mutations).

## Structure
The NHLRC1 gene encodes the protein malin, which is involved in protein ubiquitination processes. Malin is composed of 395 amino acids and features a RING-type zinc finger domain in its N-terminal region, which is typically associated with ubiquitin ligase activity (Ianzano2005Lafora). This domain is crucial for the protein's function in tagging other proteins for degradation. The C-terminal region of malin contains six NHL-repeat domains, which are known for facilitating protein-protein interactions (Ianzano2005Lafora). These structural elements suggest that malin plays a significant role in cellular processes through its interactions with other proteins.

Mutations in the NHLRC1 gene can lead to alterations in the malin protein's structure and function. For instance, the missense mutation H187P is predicted to disrupt the protein structure, as indicated by a BLOSUM score of -2, and impairs malin's ability to reduce steady-state levels of laforin, a function that is essential in preventing the accumulation of Lafora bodies (Traoré2009Novel). Other mutations, such as p.L279P, affect the NHL domains and alter the subcellular localization of malin, forming perinuclear inclusions (Singh2008Lafora). These structural disruptions highlight the importance of the intact NHLRC1 protein in maintaining normal cellular functions.

## Clinical Significance
Mutations in the NHLRC1 gene, also known as EPM2B, are primarily associated with Lafora disease, a fatal autosomal recessive form of progressive myoclonus epilepsy. This condition is characterized by myoclonus, tonic-clonic seizures, visual hallucinations, intellectual decline, and progressive neurological deterioration beginning in adolescence (Couarch2011Lafora). The NHLRC1 gene encodes the malin protein, an E3 ubiquitin ligase, which interacts with laforin to regulate glycogen metabolism. Mutations in NHLRC1 disrupt this interaction, leading to the accumulation of poorly branched glycogen, known as Lafora bodies, in neurons (Pondrelli2023Prognostic; Singh2005Mutations).

Several specific mutations in NHLRC1 have been identified, including missense mutations such as C46Y, P69A, D146N, and L261P, which impair the laforin-malin complex's ability to regulate glycogen synthesis, resulting in glycogen accumulation (Couarch2011Lafora). Other mutations, like L279P and L126P, affect the subcellular localization of malin, contributing to the pathogenesis of Lafora disease by altering its normal cellular function (Singh2008Lafora). The NHLRC1 variant rs769301934 is noted as a common cause of Lafora disease in certain populations, such as in Turkey (Haryanyan2021The). These genetic alterations underscore the critical role of NHLRC1 in maintaining normal neuronal physiology and its significant impact when mutated.

## Interactions
The NHLRC1 gene encodes the protein malin, which is an E3 ubiquitin ligase involved in several protein interactions crucial for cellular processes. Malin interacts with laforin, a protein phosphatase encoded by the EPM2A gene, forming a complex that regulates glycogen metabolism. This interaction is essential for the ubiquitination and degradation of proteins involved in glycogen biosynthesis, such as the regulatory subunit R5/PTG of type 1 protein phosphatase (Worby2008Malin; Couarch2011Lafora).

Malin also interacts with components of the PI3KC3 complex, including Beclin1, Vps34, and Vps15, promoting their polyubiquitination. This interaction is specific, as the laforin/malin complex does not interact with other proteins involved in autophagosome biogenesis, such as Bcl2, AMBRA1, or ULK1 (SanchezMartin2020Regulation).

In response to proteasomal impairment, malin is recruited to aggresomes, cytoplasmic structures formed from aggregated proteins. This recruitment involves interaction with ubiquitin-conjugating enzymes like UbcH5a, suggesting malin's role in ubiquitination processes within aggresomes (Mittal2007Lafora). These interactions highlight malin's role in protein degradation and cellular stress responses.


## References


[1. (SanchezMartin2020Regulation) Pablo Sanchez-Martin, Marcos Lahuerta, Rosa Viana, Erwin Knecht, and Pascual Sanz. Regulation of the autophagic pi3kc3 complex by laforin/malin e3-ubiquitin ligase, two proteins involved in lafora disease. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1867(2):118613, February 2020. URL: http://dx.doi.org/10.1016/j.bbamcr.2019.118613, doi:10.1016/j.bbamcr.2019.118613. This article has 18 citations.](https://doi.org/10.1016/j.bbamcr.2019.118613)

[2. (Worby2008Malin) Carolyn A. Worby, Matthew S. Gentry, and Jack E. Dixon. Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (ptg). Journal of Biological Chemistry, 283(7):4069–4076, February 2008. URL: http://dx.doi.org/10.1074/jbc.m708712200, doi:10.1074/jbc.m708712200. This article has 134 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m708712200)

[3. (Couarch2011Lafora) Philippe Couarch, Santiago Vernia, Isabelle Gourfinkel-An, Gaëtan Lesca, Svetlana Gataullina, Estelle Fedirko, Oriane Trouillard, Christel Depienne, Olivier Dulac, Dominique Steschenko, Eric Leguern, Pascual Sanz, and Stéphanie Baulac. Lafora progressive myoclonus epilepsy: nhlrc1 mutations affect glycogen metabolism. Journal of Molecular Medicine, 89(9):915–925, April 2011. URL: http://dx.doi.org/10.1007/s00109-011-0758-y, doi:10.1007/s00109-011-0758-y. This article has 20 citations.](https://doi.org/10.1007/s00109-011-0758-y)

[4. (Ianzano2005Lafora) Leonarda Ianzano, Junjun Zhang, Elayne M. Chan, Xiao-Chu Zhao, Hannes Lohi, Stephen W. Scherer, and Berge A. Minassian. Lafora progressive myoclonus epilepsy mutation database-epm2a and nhlrc1 (emp2b) genes. Human Mutation, 26(4):397–397, 2005. URL: http://dx.doi.org/10.1002/humu.9376, doi:10.1002/humu.9376. This article has 46 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.9376)

[5. (Traoré2009Novel) M. Traoré, G. Landouré, W. Motley, M. Sangaré, K. Meilleur, S. Coulibaly, S. Traoré, B. Niaré, F. Mochel, A. La Pean, A. Vortmeyer, H. Mani, and K. H. Fischbeck. Novel mutation in the nhlrc1 gene in a malian family with a severe phenotype of lafora disease. neurogenetics, 10(4):319–323, March 2009. URL: http://dx.doi.org/10.1007/s10048-009-0190-4, doi:10.1007/s10048-009-0190-4. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10048-009-0190-4)

[6. (Pondrelli2023Prognostic) Federica Pondrelli, Raffaella Minardi, Lorenzo Muccioli, Corrado Zenesini, Luca Vignatelli, Laura Licchetta, Barbara Mostacci, Paolo Tinuper, Craig W. Vander Kooi, Matthew S. Gentry, and Francesca Bisulli. Prognostic value of pathogenic variants in lafora disease: systematic review and meta-analysis of patient-level data. Orphanet Journal of Rare Diseases, September 2023. URL: http://dx.doi.org/10.1186/s13023-023-02880-6, doi:10.1186/s13023-023-02880-6. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13023-023-02880-6)

[7. (Haryanyan2021The) Garen Haryanyan, Ozkan Ozdemir, Kemal Tutkavul, Aysin Dervent, Semih Ayta, Cigdem Ozkara, Baris Salman, Emrah Yucesan, Yesim Kesim, Seda Susgun, Ugur Ozbek, Betul Baykan, Sibel A. Ugur Iseri, and Nerses Bebek. The rare rs769301934 variant in nhlrc1 is a common cause of lafora disease in turkey. Journal of Human Genetics, 66(12):1145–1151, June 2021. URL: http://dx.doi.org/10.1038/s10038-021-00944-8, doi:10.1038/s10038-021-00944-8. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s10038-021-00944-8)

[8. (Singh2008Lafora) Shweta Singh, Parthasarathy Satishchandra, Susarla Krishna Shankar, and Subramaniam Ganesh. Lafora disease in the indian population:epm2a andnhlrc1 gene mutations and their impact on subcellular localization of laforin and malin. Human Mutation, 29(6):E1–E12, 2008. URL: http://dx.doi.org/10.1002/humu.20737, doi:10.1002/humu.20737. This article has 23 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20737)

[9. (Mittal2007Lafora) Shuchi Mittal, Deepti Dubey, Kazuhiro Yamakawa, and Subramaniam Ganesh. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Human Molecular Genetics, 16(7):753–762, March 2007. URL: http://dx.doi.org/10.1093/hmg/ddm006, doi:10.1093/hmg/ddm006. This article has 73 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddm006)

[10. (Singh2005Mutations) Shweta Singh, Toshimitsu Suzuki, Akira Uchiyama, Satoko Kumada, Nobuko Moriyama, Shinichi Hirose, Yukitoshi Takahashi, Hideo Sugie, Koichi Mizoguchi, Yushi Inoue, Kazue Kimura, Yukio Sawaishi, Kazuhiro Yamakawa, and Subramaniam Ganesh. Mutations in the nhlrc1 gene are the common cause for lafora disease in the japanese population. Journal of Human Genetics, 50(7):347–352, July 2005. URL: http://dx.doi.org/10.1007/s10038-005-0263-7, doi:10.1007/s10038-005-0263-7. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10038-005-0263-7)